(4-甲氧苄基)甲基砜 | 24176-67-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: (4-甲氧苄基)甲基砜
• 英文名称: (4-methoxybenzyl)methylsulfone
• 英文别名: 1-methoxy-4-[(methylsulfonyl)methyl]benzene；4-methoxybenzyl methyl sulfone；p-<(Methylsulfonyl)-methyl>-anisole；Methyl-(p-methoxy-benzyl)-sulfon；Methyl-(4-acetyl-benzyl)-sulfon；Methyl-p-methoxy-benzyl-sulfon；1-Methoxy-4-((methylsulfonyl)methyl)benzene；1-methoxy-4-(methylsulfonylmethyl)benzene
• CAS: 24176-67-8
• 化学式: C₉H₁₂O₃S
• 分子量: 200.258
• InChiKey: OXDQXXDJLBPGQO-UHFFFAOYSA-N

物化性质

• 熔点：
  110-112 °C
• 沸点：
  388.4±25.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  51.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-甲氧苄基)甲基砜 在 四丁基碘化铵 、 sodium hydride 、 caesium carbonate 作用下， 以 二甲基亚砜 、 甲苯 、 mineral oil 为溶剂， 反应 20.0h， 生成 1-(1-methanesulfonylcyclopropyl)-4-methoxybenzene
  参考文献：
  名称：

  [EN] APOL1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS D'APOL1 ET MÉTHODES D'UTILISATION

  摘要：

  Provided herein are compounds of formula (II): or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing, whereinm, n, p, R1, R2, R3, L1, L2, L3, R4, X1, X2, X3, and X4are as defined herein. Also provided are methods of preparing compounds of formula (II), or a stereoisomer or tautomer thereof, or a pharmaceutically acceptable salt of any of the foregoing. Also provided are methods of inhibiting APOL1 and methods of treating an APOL1 -mediated disease, disorder, or condition in an individual.

  公开号：

  WO2023141432A2
• 作为产物：
  描述：

  sodium 4-methoxydithiobenzoate 在 盐酸 、 mercury dichloride 、 锌 作用下， 生成 (4-甲氧苄基)甲基砜
  参考文献：
  名称：

  Mayer,R. et al., Chemische Berichte, 1966, vol. 99, p. 1393 - 1413

  摘要：

  DOI：

文献信息

• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20010027193A1

  公开（公告）日：2001-10-04

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  式1中R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2烷基基团，它们的制备以及含有它们的药物组合物。
• Azetidine derivatives, their preparation and medicaments containing them
  申请人：——

  公开号：US20020035102A1

  公开（公告）日：2002-03-21

  The invention concerns compounds of formula (1) wherein: R represents a chain (A) or (B); R 1 is methyl or ethyl; R 2 is either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R 3 and R 4 , identical or different, are either an optionally substituted aromatic or an optionally substituted heteroaromatic ring; R′ represents a hydrogen atom or a —CO—alk radical, their optical isomers, their salts, their preparation and medicines containing them. 1

  本发明涉及通式(1)的化合物，其中：R代表链(A)或(B)；R1是甲基或乙基；R2是可任选取代的芳香环或可任选取代的杂芳香环；R3和R4，相同或不同，是可任选取代的芳香环或可任选取代的杂芳香环；R′代表氢原子或—CO—烷基，它们的光学异构体，它们的盐，它们的制备方法以及含有它们的药物。
• Synthesis of Sulfones by Iron-Catalyzed Decomposition of Sulfonylhydrazones
  作者：José Barluenga、María Tomás-Gamasa、Fernando Aznar、Carlos Valdés

  DOI：10.1002/ejoc.201001492

  日期：2011.3

  The Fe-catalyzed decomposition of sulfonylhydrazones gives rise to sulfones. The reaction is quite general and allows the preparation of sulfones from a variety of aryl, alkyl, and α,β-unsaturated aldehydes and ketones. Crossover experiments reveal that the reaction is an intermolecular process, which may proceed by nucleophilic attack of the sulfinate anion on an iron carbene complex.

  磺酰腙的Fe催化分解产生砜。该反应非常普遍，允许从各种芳基、烷基和 α,β-不饱和醛和酮制备砜。交叉实验表明，该反应是一个分子间过程，可以通过亚磺酸根阴离子对铁卡宾配合物的亲核攻击来进行。
• [EN] AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES AMIDINO SERVANT D'INHIBITEURS DE PROTEASES A CYSTEINE
  申请人：AXYS PHARMACEUTICALS

  公开号：WO2004108661A1

  公开（公告）日：2004-12-16

  The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.

  本发明涉及一种抑制半胱氨酸蛋白酶的化合物，特别是包括B、K、L、F和S半胱氨酸蛋白酶，因此在治疗由这些蛋白酶介导的疾病方面具有用处。本发明涉及包含这些化合物的药物组合物以及其制备方法。
• [EN] HALOALKYL CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS<br/>[FR] COMPOSES CONTENANT UN HALOALKYLE UTILISE COMME INHIBITEURS DE CYSTEINE PROTEASE
  申请人：AXYS PHARM INC

  公开号：WO2005028454A1

  公开（公告）日：2005-03-31

  The application is directed to haloalkyl-substituted compounds of Formula (I), wherein R1, R1a, R2, R3, R4’ and E are as defined in the claims. The compounds are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. Pharmaceutical compositions comprising these compounds and their use are also disclosed.

  该应用程序针对式(I)的卤代烷基取代化合物，其中R1、R1a、R2、R3、R4'和E如索权中所定义。这些化合物是半胱氨酸蛋白酶的抑制剂，特别是卡托普斯蛋白酶B、K、L、F和S，因此可用于治疗由这些蛋白酶介导的疾病。还公开了包含这些化合物的药物组合物及其用途。